Effect of varying levels of Glycemia on CA-19.9

Authors

  • Ayesha Hafeez Department of Chemical Pathology, Combined Military Hospital, Multan Institute of Medical Sciences, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Javeria Hafeez Department of Dermatology, Combined Military Hospital, Multan Institute of Medical Sciences Multan/National University of Medical Sciences (NUMS) Pakistan
  • Izza Rehan Combined Military Hospital Multan Institute of Medical Sciences Multan/National University of Medical Sciences (NUMS) Pakistan
  • Sikandar Hayat Khan Department of Chemical Pathology, Combined Military Hospital, Multan Institute of Medical Sciences, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Qurrat-ul -Ain Department of Chemical Pathology, Combined Military Hospital, Multan Institute of Medical Sciences, Multan/National University of Medical Sciences (NUMS) Pakistan
  • Saima Zahir Department of Hematology, Combined Military Hospital Multan Institute of Medical Sciences, Multan/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i2.9374

Keywords:

CA-19.9, Fasting plasma glucose, HbA1c, Type-2 Diabetes Mellitus

Abstract

Objective: To compare differences in CA-19.9 levels among participants with and without Type 2 diabetes mellitus and to correlate increasing glycemia levels and HbA1c with CA-19.9

Study Design: Comparative cross-sectional study

Place and Duration of Study: Department of Chemical Pathology, Combined Military Hospital, Multan Pakistan, from Feb to Aug 2022.

Methodology: One hundred thirty-one patients with diabetes and without diabetes were enrolled. CA-19.9, fasting plasma glucose, HbA1c, amylase, lipase, and anthropometric parameters were assessed. Patients with diabetes were divided into three groups based on FPG and HbA1c levels to investigate the relationship between CA-19.9 and glycemic status.

Results: There was no significant difference among CA-19.9 of Controls and patients with diabetes (19.45±14.89 versus 15.83±13.98, p=0.155). FPG and HbA1c showed a moderate positive correlation to CA-19.9 (r = 0.283, p= 0.001 and r= = 0.305, p<0.001 respectively). Inter-group comparison (post-hoc analysis) showed a significant rise of CA-19.9 with increasing HbA1c in groups with HbA1c 5.61-7.0% Vs >7.0% (p=0.020), HbA1c <5.6 %Vs >7.0%(p=0.037) and with increasing FPG in groups with FPG 5.6-7.0 mmol/L Vs >7.0 mmol/L (p=0.005).
Conclusion: The glycemic status of patients with diabetes can influence their serum CA-19.9 levels, and glycemic control should be considered while interpreting these levels in such patients. T2DM patients with poor glycemic control have a higher CA of 19.9 than those with better control.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Murray MD, Burton FR, Di Bisceglie AM. Markedly elevated

serum CA 19-9 levels in association with a benign biliary

stricture due to primary sclerosing cholangitis. J Clin

Gastroenterol 2007; 41(1): 115-117.

https://doi.org/10.1097/mcg.0b013e31802dd094

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N,

Macdonald JS, et al. ASCO 2006 update of recommendations for

the use of tumor markers in gastrointestinal cancer. J Clin Oncol

; 24: 5313–5327.

https://doi.org/10.1200/jco.2006.08.2644

Saif MMS, M. Al-Asbahy W, Ali Al-Fakih A, Albadani AM.

Serum CA19–9 Levels and Pancreatic Beta Cell Destruction in

Type 2 Diabetes Mellitus Patients. J Pharm Res Int 2017; 14(6): 1-

https://doi.org/10.9734/BJPR/2016/30808

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al

Kaabi J. et al. Epidemiology of Type 2 Diabetes - Global Burden

of Disease and Forecasted Trends. J Epidemiol Glob Health 2020;

(1): 107-111. https://doi.org/10.2991/jegh.k.191028.001

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of

type 2 diabetes mellitus and its complications. Nat Rev

Endocrinol 2018; 14(2): 88-98.

https://doi.org/10.1038/nrendo.2017.151

Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional,

and national burden and trend of diabetes in 195 countries and

territories: an analysis from 1990 to 2025. Sci Rep 2020; 10(1):

https://doi.org/10.1038/s41598-020-71908-9

Meo SA, Zia I, Bukhari IA, Arain SA. Type 2 diabetes mellitus in

Pakistan: Current prevalence and future forecast. J Pak Med

Assoc 2016; 66(12): 1637-1642.

Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;

(9050): 485-489.

https://doi.org/10.1016/s0140-6736(96)05523-7

Singla R, Goyal A, Mahajan B. Effect of glycemic status on

serum CEA and CA 19-9 levels in patients of diabetes mellitus in

northern India. Int J Health Sci Res 2018; 8(2): 67-72

Everhart J, Wright D. Diabetes mellitus as a risk factor for

pancreatic cancer. A meta-analysis. JAMA 1995; 273(20): 1605-

Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A,

et al. Diabetes Prevalence Survey of Pakistan (DPS-PAK):

prevalence of type 2 diabetes mellitus and prediabetes using

HbA1c: a population-based survey from Pakistan. BMJ Open

; 9(2): e025300.

https://doi.org/10.1136/bmjopen-2018-025300

Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin

M, Kilicoglu G, et al. Type 2 diabetes mellitus and CA 19-9

levels. World J Gastroenterol 2007; 13(40): 5357-5359.

https://doi.org/10.3748/wjg.v13.i40.5357

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH,

Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers

; 1: 15019. https://doi.org/10.1038/nrdp.2015.19

Gullo L. Diabetes and the risk of pancreatic cancer. Ann Oncol

; 10 Suppl 4: 79-81.

Khan SH, Shahid R, Fazal N, Ijaz A. Comparison of Various

Abdominal Obesity Measures for Predicting Metabolic

Syndrome, Diabetes, Nephropathy, and Dyslipidemia. J Coll

Physicians Surg Pak 2019; 29(12): 1159-1164.

https://doi.org/10.29271/jcpsp.2019.12.1159

Tsena A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-

in biliary pathology.Pancreatology 2018; 18(8): 862-867.

https://doi.org/10.1016/j.pan.2018.09.004

Benhamou PY, Vuillez JP, Halimi S, Meffre G, Bachelot I.

Influence of metabolic disturbances of diabetes mellitus on

serum CA 19-9 tumor marker. Diabete Metab 1991; 17(1): 39-43.

Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19-9

level in patients with type 2 diabetes mellitus and its relation to

the metabolic control and microvascular complications. Am J

Med Sci 2011; 341(1): 28-32.

https://doi.org/10.1097/MAJ.0b013e3181f0e2a0

Yu H, Li R, Zhang L, Chen H, Bao Y, Jia W. Serum CA19-9 level

associated with metabolic control and pancreatic beta cell

function in diabetic patients. Exp Diabetes Res 2012; 2012:

https://doi.org/10.1155/2012/745189

Kim S, Park BK, Seo JH. Carbohydrate antigen 19-9 elevation

without evidence of malignant or pancreatobiliary diseases. Sci

Rep 2010; 10: 8820. https://doi.org/10.1038/s41598-020-65720-8

Downloads

Published

29-04-2024

How to Cite

1.
Hafeez A, Hafeez J, Rehan I, Khan SH, -Ain Q- ul, Zahir S. Effect of varying levels of Glycemia on CA-19.9. Pak Armed Forces Med J [Internet]. 2024 Apr. 29 [cited 2024 May 24];74(2):446-50. Available from: https://pafmj.org/PAFMJ/article/view/9374

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 > >>